Hunan Er-Kang Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Hunan Er-Kang Pharmaceutical's earnings have been declining at an average annual rate of -30.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 11.9% per year.
Key information
-30.3%
Earnings growth rate
-30.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -11.9% |
| Return on equity | -5.8% |
| Net Margin | -21.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Subdued Growth No Barrier To Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) With Shares Advancing 27%
Sep 30
Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
Sep 26What Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) 28% Share Price Gain Is Not Telling You
Aug 08Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?
Jun 03Pinning Down Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) P/S Is Difficult Right Now
Mar 27Revenue & Expenses Breakdown
How Hunan Er-Kang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,192 | -261 | 354 | 51 |
| 30 Jun 24 | 1,354 | -241 | 358 | 56 |
| 31 Mar 24 | 1,512 | -218 | 396 | 58 |
| 31 Dec 23 | 1,783 | -195 | 395 | 57 |
| 30 Sep 23 | 1,999 | 50 | 414 | 57 |
| 30 Jun 23 | 2,050 | 68 | 391 | 51 |
| 31 Mar 23 | 1,991 | 49 | 363 | 47 |
| 01 Jan 23 | 1,871 | 46 | 360 | 48 |
| 30 Sep 22 | 1,971 | -913 | 360 | 48 |
| 30 Jun 22 | 2,273 | -855 | 397 | 46 |
| 31 Mar 22 | 2,278 | -813 | 409 | 48 |
| 01 Jan 22 | 2,235 | -791 | 406 | 49 |
| 30 Sep 21 | 2,182 | 169 | 409 | 49 |
| 30 Jun 21 | 2,012 | 220 | 381 | 46 |
| 31 Mar 21 | 2,325 | 215 | 380 | 47 |
| 31 Dec 20 | 2,382 | 192 | 386 | 48 |
| 30 Sep 20 | 2,576 | 175 | 411 | 47 |
| 30 Jun 20 | 2,596 | 96 | 444 | 53 |
| 31 Mar 20 | 2,432 | 95 | 441 | 55 |
| 31 Dec 19 | 2,744 | 159 | 465 | 55 |
| 30 Sep 19 | 2,757 | 84 | 477 | 55 |
| 30 Jun 19 | 2,720 | 124 | 455 | 56 |
| 31 Mar 19 | 2,618 | 199 | 463 | 61 |
| 01 Jan 19 | 2,354 | 217 | 432 | 56 |
| 30 Sep 18 | 2,105 | 265 | 415 | 60 |
| 30 Jun 18 | 2,218 | 321 | 335 | 106 |
| 31 Mar 18 | 2,542 | 407 | 324 | 86 |
| 31 Dec 17 | 2,828 | 522 | 316 | 79 |
| 30 Sep 17 | 3,080 | 628 | 302 | 61 |
| 30 Jun 17 | 2,998 | 691 | 361 | 0 |
| 31 Mar 17 | 2,972 | 846 | 354 | 0 |
| 31 Dec 16 | 2,706 | 795 | 347 | 0 |
| 30 Sep 16 | 2,423 | 900 | 299 | 0 |
| 30 Jun 16 | 2,280 | 847 | 278 | 0 |
| 31 Mar 16 | 1,971 | 683 | 262 | 0 |
| 31 Dec 15 | 1,756 | 605 | 247 | 0 |
| 30 Sep 15 | 1,619 | 517 | 267 | 0 |
| 30 Jun 15 | 1,442 | 434 | 265 | 0 |
| 31 Mar 15 | 1,330 | 320 | 249 | 0 |
| 31 Dec 14 | 1,370 | 288 | 236 | 0 |
| 30 Sep 14 | 1,351 | 265 | 183 | 0 |
| 30 Jun 14 | 1,328 | 252 | 166 | 0 |
| 31 Mar 14 | 1,168 | 218 | 148 | 0 |
| 31 Dec 13 | 1,011 | 193 | 143 | 0 |
Quality Earnings: 300267 is currently unprofitable.
Growing Profit Margin: 300267 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300267 is unprofitable, and losses have increased over the past 5 years at a rate of 30.3% per year.
Accelerating Growth: Unable to compare 300267's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300267 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 300267 has a negative Return on Equity (-5.8%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 21:25 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hunan Er-Kang Pharmaceutical Co., Ltd is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Jing Qiang | China International Capital Corporation Limited |